FDA delays decision on key Alexion drug by 3 months

September 4, 2015 12:54 PM

20 0

Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp.

European health regulators on Tuesday approved the drug, Kanuma, to treat lysosomal acid lipase deficiency (LAL-D), a progressive metabolic disease that often leads to liver failure, multi-organ damage and premature death.

Also read: Valeant prices psoriasis treatment at $3,500 per month

Read more

To category page